TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Cannabist Company Holdings ( (TSE:CBST) ) is now available.
The Cannabist Company announced it will release its third-quarter 2025 financial results on November 10, 2025, after the U.S. financial markets close. This announcement is significant as it provides stakeholders with insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (TSE:CBST) stock is a Hold with a C$0.50 price target. To see the full list of analyst forecasts on Cannabist Company Holdings stock, see the TSE:CBST Stock Forecast page.
Spark’s Take on TSE:CBST Stock
According to Spark, TipRanks’ AI Analyst, TSE:CBST is a Neutral.
The overall stock score of 44 reflects significant financial challenges, including declining revenues, high debt, and negative cash flows. While there are some operational improvements noted in the earnings call, the technical analysis indicates a lack of momentum and potential overbought conditions. The negative P/E ratio and lack of dividend yield further weigh down the valuation.
To see Spark’s full report on TSE:CBST stock, click here.
More about Cannabist Company Holdings
The Cannabist Company, previously known as Columbia Care, is a prominent player in the cannabis industry, with operations in 12 U.S. jurisdictions. The company manages 78 facilities, including dispensaries and cultivation sites, and offers a wide range of cannabis products such as flower, edibles, oils, and tablets. It serves both medical and adult-use markets and is known for brands like dreamt, Seed & Strain, and Triple Seven.
Technical Sentiment Signal: Sell
Current Market Cap: C$227.8M
Find detailed analytics on CBST stock on TipRanks’ Stock Analysis page.